Invivyd Inc (IVVD)

$1.38 -0.07 (-4.83%)
Market Cap 389.98M
Revenue (ttm) 53.43M
Net Income (ttm) -52.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.24%
Debt to Equity Ratio 0.00
Volume 6,698,500
Avg Vol 2,858,962
Day's Range N/A - N/A
Shares Out 282.60M
Stochastic %K 1%
Beta 0.61
Analysts Strong Sell
Price Target $10.00

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Website: invivyd.com
Address:
1601 Trapelo Road, Suite 178, Waltham, United States
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Mar. 21 at 2:18 PM
$IVVD
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 21 at 1:03 AM
$IVVD I'm controlling 320,000 shares via options and common. I hope I get the chance to add more at a buck gimme dat, I will load this fucking boat.
0 · Reply
alexx013
alexx013 Mar. 20 at 8:39 PM
$IVVD I'm back in with starter @ 1.38
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 6:44 PM
$IVVD RSI: 33.66, MACD: -0.0793 Vol: 0.13, MA20: 1.69, MA50: 1.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OceanThunder7
OceanThunder7 Mar. 20 at 5:51 PM
$IVVD Cut bait 20k loss Trash…Reminder to self, never ever buy Bio again
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 20 at 5:23 PM
$IVVD https://seekingalpha.com/article/4884540-invivyd-logical-bull-thesis-with-major-catalyst-approaching?share_source=shared_news?source=tweet
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 19 at 8:17 PM
$IVVD s
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 18 at 7:27 PM
$IVVD
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 18 at 1:23 AM
$IVVD Still here ya'll there is absolutely no reason to panic. We are going to hit stat sig on both p3's and will have a safety profile significantly better then standard vax's.
1 · Reply
billsmall
billsmall Mar. 17 at 3:06 PM
$IVVD laughing my ass off! 👇
2 · Reply
Latest News on IVVD
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Mar 20, 2026, 11:22 AM EDT - 1 day ago

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 11:25 AM EST - 16 days ago

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:03 AM EST - 16 days ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 5, 2026, 7:01 AM EST - 16 days ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mar 2, 2026, 4:10 PM EST - 19 days ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:01 PM EST - 19 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Feb 24, 2026, 7:01 AM EST - 25 days ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Feb 3, 2026, 7:01 AM EST - 6 weeks ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 20, 2026, 7:01 AM EST - 2 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jan 8, 2026, 7:01 AM EST - 2 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:05 AM EST - 3 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 3 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 4 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 4 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18, 2025, 3:49 PM EST - 4 months ago

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Nov 18, 2025, 8:23 AM EST - 4 months ago

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HD HP

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 4 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 4 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 11:36 AM EST - 4 months ago

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 4 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 4 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Oct 30, 2025, 11:36 PM EDT - 5 months ago

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 5 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 6 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 6 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 7 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Aug 29, 2025, 9:55 AM EDT - 7 months ago

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 7 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 7 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 7 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 7 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 7 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 7 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 8 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 8 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 9 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 9 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 10 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 11:08 AM EDT - 11 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 11 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 11 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 11 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 11 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Apr 21, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 1 year ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 1 year ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Mar. 21 at 2:18 PM
$IVVD
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 21 at 1:03 AM
$IVVD I'm controlling 320,000 shares via options and common. I hope I get the chance to add more at a buck gimme dat, I will load this fucking boat.
0 · Reply
alexx013
alexx013 Mar. 20 at 8:39 PM
$IVVD I'm back in with starter @ 1.38
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 6:44 PM
$IVVD RSI: 33.66, MACD: -0.0793 Vol: 0.13, MA20: 1.69, MA50: 1.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OceanThunder7
OceanThunder7 Mar. 20 at 5:51 PM
$IVVD Cut bait 20k loss Trash…Reminder to self, never ever buy Bio again
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 20 at 5:23 PM
$IVVD https://seekingalpha.com/article/4884540-invivyd-logical-bull-thesis-with-major-catalyst-approaching?share_source=shared_news?source=tweet
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 19 at 8:17 PM
$IVVD s
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 18 at 7:27 PM
$IVVD
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 18 at 1:23 AM
$IVVD Still here ya'll there is absolutely no reason to panic. We are going to hit stat sig on both p3's and will have a safety profile significantly better then standard vax's.
1 · Reply
billsmall
billsmall Mar. 17 at 3:06 PM
$IVVD laughing my ass off! 👇
2 · Reply
OceanThunder7
OceanThunder7 Mar. 17 at 2:33 PM
$IVVD I'm out!!!!!! Cannot figure out why we are not 5 probable goes up now....
2 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Mar. 17 at 4:50 AM
$GUTS $IVVD so the same guys turning around IVVD are running GUTS. and peter thiel is part of this
3 · Reply
gb2017384
gb2017384 Mar. 16 at 7:11 PM
$IVVD ,2more months of THE SHORTING .
0 · Reply
OceanThunder7
OceanThunder7 Mar. 16 at 6:24 PM
$IVVD $MVST both these hit lucky 7 this year. Question is which one does it first
0 · Reply
OceanThunder7
OceanThunder7 Mar. 16 at 2:49 PM
$IVVD we should be in the 3's CRAZY
1 · Reply
CaptE518
CaptE518 Mar. 16 at 2:37 PM
$IVVD Hahaha. The manipulation is real here. Its so obvious and funny that they get away with this crap.
0 · Reply
OceanThunder7
OceanThunder7 Mar. 16 at 1:59 PM
$IVVD another 5x potential move with this one $SPY $IBB $XBI
0 · Reply
47F
47F Mar. 16 at 10:59 AM
$IVVD @OceanThunder7 I own IVVD stock but I can’t understand who are you making all of these posts to? yourself? I don’t think it helps move the stock any when 99% of the posts come from you.
1 · Reply
OceanThunder7
OceanThunder7 Mar. 13 at 8:54 PM
$IVVD paint the tape
2 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 13 at 8:35 PM
$IVVD what was that close?
1 · Reply
OceanThunder7
OceanThunder7 Mar. 13 at 3:45 PM
$MVST $IVVD Everyone our time will come. Be patient and have a wonderful fun filled weekend. Expect the unexpected these days....
0 · Reply
OceanThunder7
OceanThunder7 Mar. 13 at 1:56 PM
I have been saying and will say it again on $IVVD shares are tight, very tight. $IBB $XBI $BIB $QQQ
0 · Reply